Stock Scorecard
Stock Summary for Bristol-Myers Squibb Company (BMY) - $44.39 as of 10/22/2025 8:29:20 PM EST
Total Score
11 out of 30
Safety Score
62 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for BMY
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for BMY
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for BMY
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for BMY
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for BMY (62 out of 100)
| Stock Price Rating (Max of 10) | 8 |
| Historical Stock Price Rating (Max of 10) | 9 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 4 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 8 |
| Operating Margin (Max of 10) | 6 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 8 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for BMY
Financial Details for BMY
Company Overview |
|
|---|---|
| Ticker | BMY |
| Company Name | Bristol-Myers Squibb Company |
| Country | USA |
| Description | Bristol-Myers Squibb Company (BMY) is a prominent global biopharmaceutical leader headquartered in New York City, renowned for its innovation in the discovery and delivery of transformative medicines. With a strategic focus on key therapeutic areas such as oncology, cardiovascular disease, immunology, and hematology, the company boasts a diverse portfolio that includes several well-established, market-leading therapies. BMS's dedication to addressing significant unmet medical needs, coupled with a robust development pipeline and strategic collaborations, positions it advantageously within the competitive pharmaceutical landscape. The company's ongoing commitment to advancing healthcare through cutting-edge research and development underscores its potential for sustained growth and impact in the biopharmaceutical sector. |
| Sector Name | HEALTHCARE |
| Industry Name | DRUG MANUFACTURERS - GENERAL |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 10/30/2025 |
Stock Price History |
|
| Last Day Price | 44.39 |
| Price 4 Years Ago | 52.94 |
| Last Day Price Updated | 10/22/2025 8:29:20 PM EST |
| Last Day Volume | 13,879,567 |
| Average Daily Volume | 16,457,998 |
| 52-Week High | 61.00 |
| 52-Week Low | 42.38 |
| Last Price to 52 Week Low | 4.74% |
Valuation Measures |
|
| Trailing PE | 17.89 |
| Industry PE | 25.46 |
| Sector PE | 40.29 |
| 5-Year Average PE | 16.47 |
| Free Cash Flow Ratio | 7.17 |
| Industry Free Cash Flow Ratio | 37.76 |
| Sector Free Cash Flow Ratio | 29.76 |
| Current Ratio Most Recent Quarter | 1.21 |
| Total Cash Per Share | 6.19 |
| Book Value Per Share Most Recent Quarter | 8.57 |
| Price to Book Ratio | 5.34 |
| Industry Price to Book Ratio | 10.65 |
| Sector Price to Book Ratio | 32.15 |
| Price to Sales Ratio Twelve Trailing Months | 1.90 |
| Industry Price to Sales Ratio Twelve Trailing Months | 3.84 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.11 |
| Analyst Buy Ratings | 3 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 2,035,436,000 |
| Market Capitalization | 90,353,004,040 |
| Institutional Ownership | 82.68% |
Dividends |
|
| Ex-Dividend Date | 10/3/2025 |
| Previous Dividend Amount | 0.6200 |
| Current Dividend Amount | 0.6200 |
| Total Years Dividend Increasing | 3 |
| Trailing Annual Dividend Rate | 2.48 |
| Trailing Annual Dividend Yield | 5.68% |
| Forward Annual Dividend Rate | 2.48 |
| Forward Annual Dividend Yield | 5.68% |
| 5-Year Dividend Payments Count | 20 |
| 3-Year Average Dividend Yield | 4.68% |
| 5-Year Average Dividend Yield | 4.31% |
| 1-Year Dividend Growth Rate Percentage | 3.33% |
| 3-Year Dividend Growth Rate Percentage | 4.29% |
| 5-Year Dividend Growth Rate Percentage | 2.01% |
| All-Time Dividend Growth Rate Percentage | 7.12% |
| Dividend Payout Ratio | 99.60% |
Income Statement |
|
| Quarterly Earnings Growth YOY | -22.80% |
| Annual Earnings Growth | -211.50% |
| Reported EPS 12 Trailing Months | 2.49 |
| Reported EPS Past Year | 3.26 |
| Reported EPS Prior Year | 1.14 |
| Net Income Twelve Trailing Months | 5,049,000,000 |
| Net Income Past Year | -8,948,000,000 |
| Net Income Prior Year | 8,025,000,000 |
| Quarterly Revenue Growth YOY | 0.60% |
| 5-Year Revenue Growth | 13.06% |
| Operating Margin Twelve Trailing Months | 33.70% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 12,599,000,000 |
| Total Cash Past Year | 10,346,000,000 |
| Total Cash Prior Year | 11,464,000,000 |
| Net Cash Position Most Recent Quarter | -31,871,000,000 |
| Net Cash Position Past Year | -37,257,000,000 |
| Long Term Debt Past Year | 47,603,000,000 |
| Long Term Debt Prior Year | 36,653,000,000 |
| Total Debt Most Recent Quarter | 44,470,000,000 |
| Equity to Debt Ratio Past Year | 0.26 |
| Equity to Debt Ratio Most Recent Quarter | 0.28 |
| Total Stockholder Equity Past Year | 16,335,000,000 |
| Total Stockholder Equity Prior Year | 29,430,000,000 |
| Total Stockholder Equity Most Recent Quarter | 17,435,000,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 14,578,000,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 7.16 |
| Free Cash Flow Past Year | 13,942,000,000 |
| Free Cash Flow Prior Year | 12,651,000,000 |
Options |
|
| Put/Call Ratio | 0.50 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.52 |
| MACD Signal | -0.45 |
| 20-Day Bollinger Lower Band | 42.68 |
| 20-Day Bollinger Middle Band | 45.67 |
| 20-Day Bollinger Upper Band | 48.66 |
| Beta | 0.34 |
| RSI | 41.23 |
| 50-Day SMA | 50.37 |
| 150-Day SMA | 51.13 |
| 200-Day SMA | 54.02 |
System |
|
| Modified | 10/22/2025 7:11:57 PM EST |